文献速递糖尿病肥胖与代谢综合征

恩格列净在冠脉搭桥术后2型糖尿病患者中的心血管与肾脏结局:EMPA-REG OUTCOME事后分析

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
PubMed 文献 · Diabetologia · 2018-05-19

该事后分析基于EMPA-REG OUTCOME随机双盲安慰剂对照试验,比较恩格列净与安慰剂在合并心血管疾病的2型糖尿病患者中的结局。有冠脉搭桥术史者占恩格列净组25%(1175/4687)和安慰剂组24%(563/2333)。恩格列净使有搭桥史患者的心血管死亡风险HR 0.52(95%CI 0.32,0.84)、全因死亡HR 0.57(95%CI 0.39,0.83)、心衰住院HR 0.50(95%CI 0.32,0.77)及新发或恶化肾病HR 0.65(95%CI 0.50,0.84)均降低。

要点

  • 合并搭桥史的2型糖尿病患者使用恩格列净后心血管死亡风险较安慰剂降低(HR 0.52)。
  • 全因死亡(HR 0.57)与心衰住院(HR 0.50)风险亦较安慰剂降低。
  • 新发或恶化肾病风险较安慰剂降低(HR 0.65),亚组交互作用均p>0.05。

核心结论

  • 在有冠脉搭桥术史的2型糖尿病患者中,恩格列净治疗与心血管死亡、全因死亡、心衰住院及新发或恶化肾病的大幅降低相关。
  • 作者认为这些数据对2型糖尿病患者搭桥术后心血管事件的二级预防有重要意义。

研究设计与样本

  • EMPA-REG OUTCOME试验为随机、双盲、安慰剂对照试验,患者按1:1:1随机接受安慰剂、恩格列净10 mg或恩格列净25 mg每日一次,均加标准治疗。
  • 本分析按基线自报冠脉搭桥术史(是/否)分层,采用Cox比例风险模型评估恩格列净与安慰剂的风险差异。
  • 有搭桥史者占恩格列净组25%(1175/4687)和安慰剂组24%(563/2333)。

主要发现

  • 有搭桥史者中,恩格列净vs安慰剂的心血管死亡HR 0.52(95%CI 0.32,0.84)。
  • 有搭桥史者中,恩格列净vs安慰剂的全因死亡HR 0.57(95%CI 0.39,0.83)。
  • 有搭桥史者中,恩格列净vs安慰剂的心衰住院HR 0.50(95%CI 0.32,0.77)。
  • 有搭桥史者中,恩格列净vs安慰剂的新发或恶化肾病HR 0.65(95%CI 0.50,0.84)。
  • 有无搭桥史者间结果一致,治疗与亚组交互作用p>0.05。

关键数值与推荐

  • 新发或恶化肾病定义为进展至大量白蛋白尿、血清肌酐加倍、启动肾脏替代治疗或肾脏疾病死亡。
  • 在总体EMPA-REG OUTCOME人群中,恩格列净vs安慰剂使心血管死亡风险降低38%、全因死亡降低32%、心衰住院降低35%、新发或恶化肾病降低39%。

临床怎么用

  • 作者认为这些数据对2型糖尿病患者搭桥术后心血管事件的二级预防有重要意义。

局限性

  • 本分析为事后分析。
  • 冠脉搭桥术史为自报,而非经病历核实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: After coronary artery bypass graft (CABG) surgery in individuals with type 2 diabetes, there remains a considerable residual cardiovascular risk. In the EMPA-REG OUTCOME® trial in participants with type 2 diabetes and established cardiovascular disease, empagliflozin reduced the risk of cardiovascular death by 38%, all-cause mortality by 32%, hospitalisation for heart failure by 35% and incident or worsening nephropathy by 39% vs placebo when given in addition to standard of care. The aim of this post hoc analysis of the EMPA-REG OUTCOME® trial was to determine the effects of the sodium glucose cotransporter 2 inhibitor empagliflozin on cardiovascular events and mortality in participants with type 2 diabetes and a self-reported history of CABG surgery. METHODS: The EMPA-REG OUTCOME® trial was a randomised, double-blind, placebo-controlled trial. Participants with type 2 diabetes and established cardiovascular disease were randomised 1:1:1 to receive placebo, empagliflozin 10 mg or empagliflozin 25 mg, once daily, in addition to standard of care. In subgroups by self-reported history of CABG (yes/no) at baseline, we assessed: cardiovascular death; all-cause mortality; hospitalisation for heart failure; and incident or worsening nephropathy (progression to macroalbuminuria, doubling of serum creatinine, initiation of renal replacement therapy or death due to renal disease). Differences in risk between empagliflozin and placebo were assessed using a Cox proportional hazards model. RESULTS: At baseline, 25% (1175/4687) of participants who received empagliflozin and 24% (563/2333) of participants who received placebo had a history of CABG surgery. In participants with a history of CABG surgery, HRs (95% CI) with empagliflozin vs placebo were 0.52 (0.32, 0.84) for cardiovascular mortality, 0.57 (0.39, 0.83) for all-cause mortality, 0.50 (0.32, 0.77) for hospitalisation for heart failure and 0.65 (0.50, 0.84) for incident or worsening nephropathy. Results were consistent between participants with and without a history of CABG surgery (p > 0.05 for treatment by subgroup interactions). CONCLUSIONS/INTERPRETATION: In participants with type 2 diabetes and a self-reported history of CABG surgery, treatment with empagliflozin was associated with profound reductions in cardiovascular and all-cause mortality, hospitalisation for heart failure, and incident or worsening nephropathy. These data have important implications for the secondary prevention of cardiovascular events after CABG in individuals with type 2 diabetes. TRIAL REGISTRATION: ClinicalTrials.gov NCT01131676.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Verma S, Mazer CD, Fitchett D, et al. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial. Diabetologia. 2018. PMID: 29777264. doi:10.1007/s00125-018-4644-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。